Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

UPADACITINIB for Dermatitis: Side Effects & Safety Data

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

There are 44 adverse event reports in the FDA FAERS database where UPADACITINIB was used for Dermatitis.

Most Reported Side Effects for UPADACITINIB

Side Effect Reports % Deaths Hosp.
Pain 4,444 6.8% 97 1,079
Arthralgia 3,815 5.8% 92 882
Drug ineffective 3,384 5.2% 42 603
Covid-19 2,978 4.5% 126 1,022
Rheumatoid arthritis 2,730 4.2% 98 633
Pain in extremity 2,353 3.6% 86 521
Fatigue 2,153 3.3% 96 576
Fall 2,081 3.2% 48 944
Surgery 2,037 3.1% 3 261
Therapy interrupted 1,741 2.7% 2 67
Pneumonia 1,645 2.5% 195 1,108
Headache 1,574 2.4% 90 400
Death 1,468 2.2% 1,414 123
Back pain 1,461 2.2% 14 431
Peripheral swelling 1,455 2.2% 88 420

Other Indications for UPADACITINIB

Rheumatoid arthritis (33,555) Product used for unknown indication (9,737) Dermatitis atopic (5,263) Colitis ulcerative (4,800) Crohn's disease (4,390) Psoriatic arthropathy (3,556) Ankylosing spondylitis (1,440) Psoriasis (732) Eczema (261) Rheumatoid factor positive (208)

Other Drugs Used for Dermatitis

DUPILUMAB (9,959) CRISABOROLE (407) APREMILAST (122) TRALOKINUMAB-LDRM (90) KETOCONAZOLE (66) CYCLOSPORINE (62) DOXYCYCLINE (57) PIMECROLIMUS (55) CLOBETASOL (50) RUXOLITINIB (50)

Related Pages

UPADACITINIB Full Profile All Dermatitis Drugs UPADACITINIB Demographics UPADACITINIB Timeline